Intellia Therapeutics (NTLA) Upgraded to “Buy” at BidaskClub

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday.

Several other research firms have also weighed in on NTLA. Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, May 1st. TheStreet lowered Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Monday, May 7th. Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, March 15th. ValuEngine raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. Finally, Chardan Capital raised Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $34.83.

NTLA opened at $25.98 on Wednesday. The firm has a market cap of $1.09 billion, a PE ratio of -13.82 and a beta of 2.85. Intellia Therapeutics has a fifty-two week low of $24.72 and a fifty-two week high of $25.64.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Tuesday, May 1st. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.07. The business had revenue of $7.47 million during the quarter, compared to analyst estimates of $6.14 million. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%. research analysts anticipate that Intellia Therapeutics will post -2 earnings per share for the current year.

In other news, insider John M. Leonard sold 8,400 shares of the firm’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total value of $201,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jean Francois Formela sold 39,245 shares of the firm’s stock in a transaction on Tuesday, March 20th. The stock was sold at an average price of $23.87, for a total value of $936,778.15. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,331 shares of company stock valued at $1,305,796. 12.80% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the company. D.A. Davidson & CO. purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $323,000. K.J. Harrison & Partners Inc purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $308,000. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 269.2% during the fourth quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock worth $26,430,000 after acquiring an additional 1,002,671 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Intellia Therapeutics by 1.9% during the fourth quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock worth $32,885,000 after acquiring an additional 31,662 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Intellia Therapeutics by 306.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 129,900 shares of the company’s stock worth $2,497,000 after acquiring an additional 97,936 shares in the last quarter. 54.70% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply